Everolimus alleviates CD4

Jack Donato Rockhold, Heather Marszalkowski, Marco Sannella, Kaleigh Gibney, Lyanne Murphy, Emelia Zukowski, Gabriella H Kalantar, Sara SantaCruz-Calvo, Samantha N Hart, Madison K Kuhn, Jingting Yu, Olivia Stefanik, Gabrielle Chase, Elizabeth A Proctor, Hatice Hasturk, Barbara S Nikolajczyk, Leena P Bharath

Department of Health Sciences and Nutrition, Merrimack College, North Andover, MA, USA.Department of Health Sciences and Nutrition, Merrimack College, North Andover, MA, USA. · pubmed

Paper

Abstract

Aging is associated with the onset and progression of multiple diseases, which limit health span. Chronic low-grade inflammation in the absence of overt infection is considered the simmering source that triggers age-associated diseases. Failure of many cellular processes during aging is mechanistically linked to inflammation; however, the overall decline in the cellular homeostasis mechanism of autophagy has emerged as one of the top and significant inducers of inflammation during aging, frequently known as inflammaging. Thus, physiological or pharmacological interventions aimed at improving autophagy are considered geroprotective. Rapamycin analogs (rapalogs) are known for their ability to inhibit mTOR and thus regulate autophagy. This study assessed the efficacy of everolimus, a rapalog, in regulating inflammatory cytokine production in T cells from older adults. CD4

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper addresses the role of everolimus, a rapalog, in regulating inflammatory cytokine production in T cells from older adults, which is directly related to the mechanisms of aging and inflammation. By focusing on autophagy and its link to inflammaging, the study contributes to understanding potential interventions that could mitigate age-related diseases. However, while the research is solid, it appears to be an incremental advance rather than a groundbreaking discovery, hence the moderate impact score.

Author of this paper? Send a correction.